ReviewCurrent neurology and neuroscience reports2026
Update on the Pathophysiology and Management of Tics.
Review in Current neurology and neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to collate takeaways from the most recent and relevant literature related to tics, from genetic studies to case studies elucidating Functional tic like behaviors (FTLBs) and clinical trials of novel drugs in development. RECENT
findingsRecent genome-wide association studies (GWAS) and functional neuroimaging studies have enhanced the understanding of genetic and structural links to Tourette Syndrome (TS). The rise of FTLBs during the Covid-19 pandemic heightened our understanding of this phenomenon and led to the identification of social media’s influence on tics. New studies have identified sex-related difference in TS and common psychiatric co-morbidities. Tic treatment is evolving away from traditional anti-psychotics toward newer compounds including VMAT-2 inhibitors, Ecopipam, and cannabinoid formulations, as well as novel transcranial stimulation approaches. Our understanding of tic etiology and pathophysiology as well tics’ functional counterpart FTLBs and social media impact is expanding along with our ability to manage tics with novel treatments in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.